What is Leerink Partnrs' Forecast for Metsera Q3 Earnings?

Key Points

• Leerink Partners forecasts Metsera Inc. to report a Q3 2025 earnings per share (EPS) of ($0.56), maintaining a "Strong-Buy" rating on the stock.
• Recent estimates from Leerink predict Metsera's earnings for FY2025 to be ($2.10) EPS, with projected losses increasing through FY2029.
• Institutional investors, including Alphabet Inc., have significantly increased their stakes in Metsera, with substantial new positions acquired in the first quarter of the year.

Metsera Inc. (NASDAQ:MTSR - Free Report) - Stock analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Metsera in a research note issued on Tuesday, September 9th. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of ($0.56) for the quarter. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for Metsera's Q4 2025 earnings at $0.00 EPS, FY2025 earnings at ($2.10) EPS, FY2026 earnings at ($3.32) EPS, FY2027 earnings at ($3.77) EPS, FY2028 earnings at ($3.80) EPS and FY2029 earnings at ($4.92) EPS.

Metsera (NASDAQ:MTSR - Get Free Report) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

MTSR has been the topic of a number of other research reports. Wall Street Zen lowered Metsera from a "hold" rating to a "sell" rating in a report on Sunday. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a report on Wednesday, September 3rd. Bank of America lifted their price objective on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Guggenheim lifted their price objective on Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Finally, Leerink Partners began coverage on Metsera in a report on Tuesday. They issued an "outperform" rating and a $77.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $63.50.

Metsera Price Performance

NASDAQ MTSR opened at $36.50 on Thursday. Metsera has a 52-week low of $12.30 and a 52-week high of $47.40. The business's 50-day moving average price is $35.21 and its 200 day moving average price is $28.76.

Institutional Investors Weigh In On Metsera

Institutional investors have recently modified their holdings of the company. Alphabet Inc. purchased a new stake in Metsera in the 1st quarter valued at approximately $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in Metsera in the 1st quarter valued at $78,748,000. Wellington Management Group LLP acquired a new position in Metsera in the 1st quarter valued at $65,382,000. Alpha Wave Global LP acquired a new position in Metsera in the 1st quarter valued at $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in Metsera in the 1st quarter valued at $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.